JP2021500405A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500405A5 JP2021500405A5 JP2020542711A JP2020542711A JP2021500405A5 JP 2021500405 A5 JP2021500405 A5 JP 2021500405A5 JP 2020542711 A JP2020542711 A JP 2020542711A JP 2020542711 A JP2020542711 A JP 2020542711A JP 2021500405 A5 JP2021500405 A5 JP 2021500405A5
- Authority
- JP
- Japan
- Prior art keywords
- prodrug
- page
- patent document
- active drug
- prior
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
プロドラッグは、典型的には、活性薬物の代替形態であり、プロドラッグを不活性にするか、溶解性、安定性、または生物学的利用能を与えるか、または活性薬物の他のいくつかの特性を変える化学基で可逆的に修飾または誘導体化される。典型的には、プロドラッグの化学基は、熱、キャビテーション、圧力、ｐＨ変化、還元−酸化、および／またはプロドラッグに作用する酵素活性によりプロドラッグから切断され、それにより活性薬物を放出する。プロドラッグの化学基の切断は、対象への薬物送達の前に起こり得るが、一般的には、対象における酵素プロセスによってインビボで起こる。
この出願の発明に関連する先行技術文献情報としては、以下のものがある（国際出願日以降国際段階で引用された文献及び他国に国内移行した際に引用された文献を含む）。
（先行技術文献）
（非特許文献）
（非特許文献１） ＷＥＳＳＥＬＳ Ｆ Ｌ ＥＴ ＡＬ，"Ｓｙｎｔｈｅｓｉｓ ａｎｄ ｓｋｅｌｅｔａｌ ｍｕｓｃｌｅ ｒｅｌａｘａｎｔ ａｃｔｉｖｉｔｙ ｏｆ ３−（ａｍｉｎｏａｃｙｌ）−１−［［［５−（ｓｕｂｓｔｉｔｕｔｅｄ ｐｈｅｎｙｌ）−２−ｆｕｒａｎｙｌ］ｍｅｔｈｙｌｅｎｅ］ａｍｉｎｏ］−２，４−ｉｍｉｄａｚｏｌｉｄｉｎｅｄｉｏｎｅｓ"， ＤＩＳＳＯＬＵＴＩＯＮ ＰＲＯＦＩＬＥ ＯＦ ＮＯＶＥＬ ＣＯＭＰＯＳＩＴＥ ＰＥＬＬＥＴ ＣＯＲＥＳ ＢＡＳＥＤ ＯＮ ＤＩＦＦＥＲＥＮＴ ＲＡＴＩＯＳ ＯＦ ＭＩＣＲＯＣＲＹＳＴＡＬＬＩＮＥ ＣＥＬＬＵＬＯＳＥ ＡＮＤ ＩＳＯＭＡＬＴ， ＪＯＵＲＮＡＬ ＯＦ ＰＨＡＲＭＡＣＥＵＴＩＣＡＬ ＳＣＩＥＮＣＥＳ，ＶＯＬ．１０１，ＮＲ．８，ＰＡＧＥ（Ｓ） ２６７５−２６８０，Ｖｏｌ．７０，Ｎｏ．９，０１ Ｓｅｐｔｅｍｂｅｒ １９８１（１９８１−０９−０１），ｐａｇｅ １０８８−１０９０
（非特許文献２） ＳＮＹＤＥＲ Ｈ Ｒ ＥＴ ＡＬ，"１−［（５−ａｒｙｌｆｕｒｆｕｒｙｌｉｄｅｎｅ）ａｍｉｎｏ］ｈｙｄａｎｔｏｉｎｓ．Ａ ｎｅｗ ｃｌａｓｓ ｏｆ ｍｕｓｃｌｅ ｒｅｌａｘａｎｔｓ"，ＪＯＵＲＮＡＬ ＯＦ ＭＥＤＩＣＩＮＡＬ ＣＨＥＭＩＳＴＲＹ，ＡＭＥＲＩＣＡＮ ＣＨＥＭＩＣＡＬ ＳＯＣＩＥＴＹ，Ｖｏｌ．１０，０１ Ｓｅｐｔｅｍｂｅｒ １９６７ （１９６７−０９−０１），ｐａｇｅ ８０７−８０９
この出願の発明に関連する先行技術文献情報としては、以下のものがある（国際出願日以降国際段階で引用された文献及び他国に国内移行した際に引用された文献を含む）。
（先行技術文献）
（非特許文献）
（非特許文献１） ＷＥＳＳＥＬＳ Ｆ Ｌ ＥＴ ＡＬ，"Ｓｙｎｔｈｅｓｉｓ ａｎｄ ｓｋｅｌｅｔａｌ ｍｕｓｃｌｅ ｒｅｌａｘａｎｔ ａｃｔｉｖｉｔｙ ｏｆ ３−（ａｍｉｎｏａｃｙｌ）−１−［［［５−（ｓｕｂｓｔｉｔｕｔｅｄ ｐｈｅｎｙｌ）−２−ｆｕｒａｎｙｌ］ｍｅｔｈｙｌｅｎｅ］ａｍｉｎｏ］−２，４−ｉｍｉｄａｚｏｌｉｄｉｎｅｄｉｏｎｅｓ"， ＤＩＳＳＯＬＵＴＩＯＮ ＰＲＯＦＩＬＥ ＯＦ ＮＯＶＥＬ ＣＯＭＰＯＳＩＴＥ ＰＥＬＬＥＴ ＣＯＲＥＳ ＢＡＳＥＤ ＯＮ ＤＩＦＦＥＲＥＮＴ ＲＡＴＩＯＳ ＯＦ ＭＩＣＲＯＣＲＹＳＴＡＬＬＩＮＥ ＣＥＬＬＵＬＯＳＥ ＡＮＤ ＩＳＯＭＡＬＴ， ＪＯＵＲＮＡＬ ＯＦ ＰＨＡＲＭＡＣＥＵＴＩＣＡＬ ＳＣＩＥＮＣＥＳ，ＶＯＬ．１０１，ＮＲ．８，ＰＡＧＥ（Ｓ） ２６７５−２６８０，Ｖｏｌ．７０，Ｎｏ．９，０１ Ｓｅｐｔｅｍｂｅｒ １９８１（１９８１−０９−０１），ｐａｇｅ １０８８−１０９０
（非特許文献２） ＳＮＹＤＥＲ Ｈ Ｒ ＥＴ ＡＬ，"１−［（５−ａｒｙｌｆｕｒｆｕｒｙｌｉｄｅｎｅ）ａｍｉｎｏ］ｈｙｄａｎｔｏｉｎｓ．Ａ ｎｅｗ ｃｌａｓｓ ｏｆ ｍｕｓｃｌｅ ｒｅｌａｘａｎｔｓ"，ＪＯＵＲＮＡＬ ＯＦ ＭＥＤＩＣＩＮＡＬ ＣＨＥＭＩＳＴＲＹ，ＡＭＥＲＩＣＡＮ ＣＨＥＭＩＣＡＬ ＳＯＣＩＥＴＹ，Ｖｏｌ．１０，０１ Ｓｅｐｔｅｍｂｅｒ １９６７ （１９６７−０９−０１），ｐａｇｅ ８０７−８０９
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023007969A JP2023061949A (ja) | 2017-10-20 | 2023-01-23 | ダントロレンの生産物およびそれらの使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762575124P | 2017-10-20 | 2017-10-20 | |
| US62/575,124 | 2017-10-20 | ||
| US201862674422P | 2018-05-21 | 2018-05-21 | |
| US62/674,422 | 2018-05-21 | ||
| PCT/US2018/056713 WO2019079721A1 (en) | 2017-10-20 | 2018-10-19 | DANTROLENE PRODRUGS AND METHODS OF USE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023007969A Division JP2023061949A (ja) | 2017-10-20 | 2023-01-23 | ダントロレンの生産物およびそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021500405A JP2021500405A (ja) | 2021-01-07 |
| JP2021500405A5 true JP2021500405A5 (ja) | 2021-09-09 |
| JP7252963B2 JP7252963B2 (ja) | 2023-04-05 |
Family
ID=64277793
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542711A Active JP7252963B2 (ja) | 2017-10-20 | 2018-10-19 | ダントロレンの生産物およびそれらの使用方法 |
| JP2023007969A Pending JP2023061949A (ja) | 2017-10-20 | 2023-01-23 | ダントロレンの生産物およびそれらの使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023007969A Pending JP2023061949A (ja) | 2017-10-20 | 2023-01-23 | ダントロレンの生産物およびそれらの使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11352347B2 (ja) |
| EP (1) | EP3697779A1 (ja) |
| JP (2) | JP7252963B2 (ja) |
| KR (1) | KR102652642B1 (ja) |
| CN (1) | CN111344286A (ja) |
| AU (2) | AU2018351494B2 (ja) |
| BR (1) | BR112020007858A2 (ja) |
| CA (1) | CA3079558A1 (ja) |
| CO (1) | CO2020006193A2 (ja) |
| IL (1) | IL274045B2 (ja) |
| MA (1) | MA50403A (ja) |
| MX (2) | MX2020003400A (ja) |
| SG (1) | SG11202003452XA (ja) |
| UA (1) | UA127738C2 (ja) |
| WO (1) | WO2019079721A1 (ja) |
| ZA (1) | ZA202002779B (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA127738C2 (uk) * | 2017-10-20 | 2023-12-20 | Іґл Рісерч Лебс Лімітед | Проліки дантролену і способи їх застосування |
| BR112021010105A2 (pt) * | 2018-11-27 | 2021-08-24 | Eagle Research Labs Limited | Uso de uma composição farmacêutica compreendendo dantroleno |
| EP3771711A1 (en) | 2019-07-29 | 2021-02-03 | Bayer Animal Health GmbH | Pyrazole derivatives for controlling arthropods |
| EP4132517A1 (en) | 2020-04-10 | 2023-02-15 | Eagle Pharmaceuticals, Inc. | Methods of treating viral infections |
| EP4132516A1 (en) | 2020-04-10 | 2023-02-15 | Eagle Pharmaceuticals, Inc. | Methods of treating severe acute respiratory syndrome |
| US20230143775A1 (en) | 2020-04-10 | 2023-05-11 | Eagle Pharmaceuticals, Inc. | Methods of treating coronavirus infections |
| IL296517A (en) | 2020-04-10 | 2022-11-01 | Eagle Pharmaceuticals Inc | Methods for treating sars-cov-2 infections |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3415821A (en) | 1965-09-07 | 1968-12-10 | Norwich Pharma Co | 1-(5-substituted)furfurylideneamino hydantoins and imidazolidinones |
| US4137402A (en) | 1978-03-30 | 1979-01-30 | Morton-Norwich Products, Inc. | Quaternary ammonium salts of dantrolene and clodanolene |
| US8975284B2 (en) * | 2007-10-09 | 2015-03-10 | Us Worldmeds Llc | Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents |
| US8536213B2 (en) * | 2007-11-16 | 2013-09-17 | Nektar Therapeutics | Oligomer-dantrolene conjugates and related compounds |
| US20090306163A1 (en) | 2008-06-10 | 2009-12-10 | Pamela Renee Lipkin | Topical compositions comprising imidazolidinedione analogs and their use to treat or prevent the appearance of skin wrinkling |
| US9725429B2 (en) | 2013-03-15 | 2017-08-08 | Rosalind Franklin University Of Medicine And Science | Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release |
| WO2014144654A1 (en) | 2013-03-15 | 2014-09-18 | Rosalind Franklin University Of Medicine And Science | Compounds for stabilizing ryanodine receptors from aberrant levels of calcium release |
| EP2994134B1 (en) | 2013-05-06 | 2021-06-23 | University Health Network | Methods of administering dantrolene for the acute treatment of cardiac arrhythmias |
| WO2014182942A1 (en) | 2013-05-08 | 2014-11-13 | Mangat Harpal S | Compositions and method for treatment of ischemic neuronal reperfusion injury |
| HUP1300720A2 (hu) | 2013-12-12 | 2015-06-29 | Univ Szegedi | Gyógyászati készítmények sebgyógyulás elõsegítésére |
| WO2015182625A1 (ja) | 2014-05-26 | 2015-12-03 | 国立大学法人京都大学 | Ｒａｓ活性阻害薬及びその用途 |
| WO2016077706A1 (en) | 2014-11-13 | 2016-05-19 | Washington University | Treatment for wolfram syndrome and other endoplasmic reticulum stress disorders |
| UA127738C2 (uk) * | 2017-10-20 | 2023-12-20 | Іґл Рісерч Лебс Лімітед | Проліки дантролену і способи їх застосування |
-
2018
- 2018-10-19 UA UAA202002979A patent/UA127738C2/uk unknown
- 2018-10-19 BR BR112020007858-1A patent/BR112020007858A2/pt unknown
- 2018-10-19 MA MA050403A patent/MA50403A/fr unknown
- 2018-10-19 WO PCT/US2018/056713 patent/WO2019079721A1/en unknown
- 2018-10-19 SG SG11202003452XA patent/SG11202003452XA/en unknown
- 2018-10-19 MX MX2020003400A patent/MX2020003400A/es unknown
- 2018-10-19 JP JP2020542711A patent/JP7252963B2/ja active Active
- 2018-10-19 AU AU2018351494A patent/AU2018351494B2/en active Active
- 2018-10-19 CA CA3079558A patent/CA3079558A1/en active Pending
- 2018-10-19 KR KR1020207013964A patent/KR102652642B1/ko active IP Right Grant
- 2018-10-19 CN CN201880068207.9A patent/CN111344286A/zh active Pending
- 2018-10-19 EP EP18801102.7A patent/EP3697779A1/en active Pending
- 2018-10-19 IL IL274045A patent/IL274045B2/en unknown
- 2018-10-19 US US16/755,255 patent/US11352347B2/en active Active
-
2020
- 2020-05-14 ZA ZA2020/02779A patent/ZA202002779B/en unknown
- 2020-05-20 CO CONC2020/0006193A patent/CO2020006193A2/es unknown
- 2020-07-13 MX MX2023010501A patent/MX2023010501A/es unknown
-
2022
- 2022-05-24 US US17/751,806 patent/US20220324850A1/en active Pending
-
2023
- 2023-01-23 JP JP2023007969A patent/JP2023061949A/ja active Pending
- 2023-12-08 AU AU2023278113A patent/AU2023278113A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500405A5 (ja) | ||
| HRP20150838T1 (hr) | Sastavi koji sadrže modulatore receptora sfingozin 1 fosfata (s1p) | |
| JP2008540649A5 (ja) | ||
| AR116035A2 (es) | Formulación farmacéutica - 514 | |
| RU2005101639A (ru) | Таблетка с замедленным высвобождением, содержащая ребоксетин | |
| JP2008110984A5 (ja) | ||
| BRPI0513846A (pt) | formulação de comprimido de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e o uso do mesmo | |
| ME01458B (me) | Kruta dozna forma koja sadrži inhibitor protonske pumpe i njena suspenzija | |
| CL2010001054A1 (es) | Mezcla pesticida que comprende la antranilamida 3- bromo-n- [4-cioan-2-metil -6- [(metilamino)- carbonil] fenil] -1-(3 cloro-2-piridinil)-1h- pirazol -5- carboxamida y un segundo agente activo selecto entre inhibidores de la colinesterasa; composiciones y metodo que emplean dicha mezcla para combatir plagas de invertebrados (divisional de 1856-2005). | |
| NO20083104L (no) | Fast preparat | |
| JP2005533780A5 (ja) | ||
| BR9910583A (pt) | Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios | |
| BRPI0518553A2 (pt) | composiÇço farmacÊutica estÁvel, mÉtodo para estabilizaÇço de pelo menos um ingrediente farmaceuticamente ativo e mÉtodo de uso de celulose microcristalina silicificada | |
| JP2002536445A5 (ja) | ||
| NO343603B1 (no) | Forbindelse for anvendelse for behandling av søvnighet på dagtid assosiert med Parkinsons sykdom eller obstruktiv søvnapné, samt kombinasjon omfattende forbindelsen med et anti-parkinson medikament. | |
| HU228516B1 (en) | Use of dopamine d3 receptor ligands for producing pharmaceutical compositions for treating kidney disorders | |
| PE20081751A1 (es) | Composicion farmaceutica que comprende un antagonista muscarinico y antagonista beta-2 adrenorreceptor | |
| JP2010511631A5 (ja) | ||
| Badavath et al. | Design, in-silico docking and predictive ADME properties of novel pyrazoline derivatives with selective human MAO inhibitory activity | |
| Markham | Solriamfetol: first global approval | |
| JP2019196384A5 (ja) | ||
| JP2020527138A5 (ja) | ||
| AlAli et al. | Exploitation of design-of-experiment approach for design and optimization of fast-disintegrating tablets for sublingual delivery of sildenafil citrate with enhanced bioavailability using fluid-bed granulation technique | |
| WO2009121155A3 (en) | Flavone containing compositions for treating mao associated disorders | |
| MA38697A1 (fr) | 4-(5-(4-chlorophényl)-2-(2-cyclopropylacétyl)-1,4-diméthyl-1h-pyrrol-3-yl)benzène-sulfonamide à titre de modulateur du nachr alpha 7 |